Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zillow

Bond investors have a lot on their plate with rising oil prices, a hawkish Bank of England, and hedge fund speculators. Can stocks build on last week's positive earnings?

Zillow, Disney, And Moderna Are Dealing With Tougher Outlooks

The vaccine maker has a promising pipeline but an expensive valuation.

Is Moderna a Good Healthcare Stock to Buy Now?

Analog Devices

GameStop

Palantir Technologies

The Alaska Department of Revenue sold most of its GameStop stock in the third quarter. It initiated positions in Moderna and Palantir stock, and bulked up its holdings in Analog Devices stock.

Alaska Slashed Its Stake in GameStop Stock. Here's What It Bought.

The company's COVID-19 vaccine has been a massive success, but how much is the underlying technology worth?

Could Moderna Justify Its $129 Billion Valuation?

The Food and Drug Administration will delay its decision on authorizing Moderna Inc's vaccine for adolescents while it examines whether it leads to an inflammatory heart condition, the Wall St. Journal has reported. The move comes after four Nordic countries have taken stronger stances against giving Moderna vaccines to younger adults. The issue surrounds myocarditis,...

FDA Will Delay Its Decision On Moderna Vaccinations For Adolescents – Wall St. Journal

Paul Sagan, who is also chairman of public-interest site ProPublica, recently sold $710,000 of shares of the Covid-19 vaccine maker.

Moderna Stock Soared This Year. A Company Director Sold a Large Block.

Novavax

Ocugen, Inc.

These COVID-19 vaccine makers are sinking on nothing more than good old-fashioned uncertainty.

Why Shares of Moderna, Novavax, and Ocugen Are Falling Today

The FDA is reportedly delaying a decision on authorizing Moderna's vaccine in adolescents.

Why Moderna Stock Fell Today

Chubb

Lam Research

Riot Blockchain

Domino's Pizza

The S&P 500, Dow Jones, and Nasdaq continued their rally into the weekend, extending gains as more positive earnings came out on Friday morning.

Friday Afternoon Analyst Upgrades and Downgrades: Chubb, Domino's, Lam Research, Moderna, Riot Blockchain and More

A day after the U.S. FDA advisors unanimously voted in favour of Moderna Inc's (NASDAQ: MRNA) booster shots, Emory University's Dr Carlos Del Rio said, “I'm not sure we need the Moderna booster”. Dr Rio's remarks on CNBC's ‘Worldwide Exchange' On CNBC's “Worldwide Exchange”, Dr Rio said the data supporting Moderna booster wasn't very strong.

Dr Carlos Del Rio: ‘I am not sure we need the Moderna booster'

Overall, side effects from a half-strength third dose of Moderna's vaccine were similar to a second dose. Younger people recorded more side effects.

The most common side effects to expect after your Moderna booster: headache, fatigue, and pain at the injection site

The shares of Moderna Inc (NASDAQ:MRNA) are up 1.7% at $337.19 this morning, adding to yesterday's 3.2% pop.

Analyst Upgrade, FDA Approval Send Moderna Stock Higher

An FDA advisory panel recommended Thursday that Moderna's Covid-19 vaccine be authorized as a third, smaller booster dose for some people.

Moderna Stock Is Rising After an Upgrade. This Analyst Says It's Time to Buy.

Johnson & Johnson

These are Insider's biggest healthcare stories for the week ending October 15.

What's in store for Moderna and J&J booster shots

The FDA may soon approve a Moderna booster after a unanimous vote by the Vaccines and Related Biological Products Advisory Committee. If you received a Moderna Covid-19 vaccine earlier this year, you may soon be able to get another dose.

Moderna booster shot update: Here's the latest news for prior vaccine recipients

Moderna, Inc. announced that the US Food and Drug Administration's vaccine advisory committee has recommended the granting of an Emergency Use Authorization (EUA) for a booster dose of the Moderna COVID-19 vaccine for people over 65 and for high-risk individuals between 18 and 64. Moderna is seeking authorisation for a 50 micrograms dose for the vaccine booster, which is half of its regular dose.

US FDA advisers back Moderna COVID-19 vaccine booster for over-65s and high-risk people

Roku

Shopify

Teladoc

These well-known and widely held companies should deliver jaw-dropping revenue growth over the next five years.

5 Big-Name Stocks Expected to Increase Sales 356% to 1,605% by 2025

Pfizer

The bar could be lower for the FDA to authorize booster shots for J&J's COVID-19 vaccine.

Could Johnson & Johnson's Booster Opportunity Be Better Than Pfizer's and Moderna's?

BioNTech SE

Delta Air Lines

Goldman Sachs

J.B. Hunt Transport Services

Southwest Airlines

Prologis

The indexes had been trying to turn around a steep drop to the start of the week, and finally managed on Thursday.

Best Single Trading Day in Months for Dow, Nasdaq, S&P

The company's coronavirus vaccine booster shot received a major boost from an FDA panel of experts.

Why Moderna Stock Trounced the Market Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces FDA Advisory committee unanimously votes in support of emergency use for a booster dose of Moderna's COVID-19 vaccine in the U.S.

Moderna Announces FDA Advisory Committee Unanimously Votes in Support of Emergency Use for a Booster Dose of Moderna's COVID-19 Vaccine in the U.S.

The vote isn't binding but the FDA is expected to accept the recommendation.

FDA advisory panel recommends Moderna booster for many adults

U.S. health advisers said Thursday that some Americans who received Moderna MRNA, +3.23% 's COVID-19 vaccine should get a half-dose booster to bolster protection against the virus.

Moderna stock rises as FDA panel recommends COVID booster for at-risk adults

Moderna Inc (NASDAQ: MRNA) is spiking higher Thursday afternoon after an FDA panel voted in favor of booster shorts of the company's COVID-19 vaccine for recipients 65 and older as well as some other vulnerable groups. The booster would be half the dose of the first two shots (50 micrograms instead of 100 micrograms).

Why Moderna Shares Are Climbing Today

The Food and Drug Administration typically follows the recommendations of this key advisory panel.

News for Moderna Stock (MRNA)